Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by: High-throughput ex vivo drug assay (2D platforms) Global transcriptome analysis by RNA sequencing Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80, CD86, HLA-DR, ...
LN, PB and BM mononuclear cells collected from CLL patients at specified timepoints will be tested by: High-throughput ex vivo drug assay (2D platforms) Global transcriptome analysis by RNA sequencing Flow cytometry including activation and adhesion/migration markers, e.g. CD69, CD80, CD86, HLA-DR, CD38, CD49d, CXCR4; Phospho-flow assays, to assess the phosphorylation state of proteins involved in BCR signaling transduction, e.g. AKT and ERK; Western blot of nuclear lysates and cytoplasmic protein fractions to validate the expression of relevant genes Targeted deep-sequencing by a previously validated panel Minimal residual disease evaluation will be performed by: 6-color flow cytometry NGS CfDNA will be analysed by targeted NGS. The following features will be evaluated by tailored ultrasound: Superficial nodal sites (linear probe 7.5 MHz): Site Size: long and short diameter (sensitivity <5 mm) Shape Border echo-structure of the cortex; assessment of possible intranodal reticulation Echogenic description of the hilum: presence, absence and irregular echo-morphology Optional parameters: Doppler evaluation: vascular distribution, vascular resistance Contrast enhanced ultrasound (CEUS): 7.5 MHz linear probe (optional);Quantitative assessment with dedicated software (wash-in and wash-out curves): optional Deep nodal sites (probe 3.5-5 MHz): Site Presence/absence of deep lymphoadenopathies Size (sensitivity <5 mm) Echo-structure of the cortex (only if superficial, e.g. external iliac LN) Optional parameters: Vascular pattern by: color doppler, two-dimensional power doppler and MicroV (only if superficial, e.g. external iliac LN) Contrast enhanced ultrasound (CEUS) (optional): vascular pattern present vs absent, intensity Spleen: Size (dedicated software to more precisely define the bipolar diameter) : in cm Cross sectional area in cm2 Optional parameters: Splenic artery resistive index Portal vein flow (forward or non-forward portal flow): Vmax ("maximum velocity expressed in cm" and "mean Velocity expressed in cm") Splenic stiffness (with Fibroscan or point share wave or share wave 2D) expressed in kPa Liver: Size Echo-structure Optional parameters: Portal vein flow parameters Liver artery resistive index Liver stiffness expressed in kPa
Tracking Information
- NCT #
- NCT04790045
- Collaborators
- Not Provided
- Investigators
- Not Provided